Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 5, 2004 Dave Marino-Nachison	Finally, Eckerd Sells J.C. Penney's drugstore operation will be split between CVS and Jean Coutu.
The Motley Fool June 10, 2004 Alyce Lomax	Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.
The Motley Fool August 4, 2004 Phil Wohl	CVS's Prescription for Competition The national drugstore chain is looking to take advantage of increased size.
The Motley Fool February 26, 2004 Alyce Lomax	Pinching J.C. Penney Eckerd is still a pain, but will Penney fly when it's on its own? Penney's reported a net loss of $1.07 billion, or $3.42 per share, as compared to earnings of $202 million, or $0.68 per share, in the same quarter last year.
The Motley Fool March 24, 2004 Dave Marino-Nachison	Eking Out an Eckerd Deal Investors are still waiting for a new leader to be crowned in the U.S. drugstore business.
The Motley Fool August 17, 2004 Nathan Slaughter	J.C. Penney on the Rise The retailer hits its stride after shedding Eckerd Drugstores.
The Motley Fool January 26, 2004 Jason Matthews	A Penney Saved Department store retailer J.C. Penney cuts jobs and restructures.
The Motley Fool June 2, 2004 Alyce Lomax	Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?
The Motley Fool March 22, 2004 Alyce Lomax	Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.
The Motley Fool July 6, 2004 Alyce Lomax	Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.
The Motley Fool December 23, 2003 Dave Marino-Nachison	Duane Reade's NY Story The well-known New York drugstore chain is going private after just under six years.
The Motley Fool February 2, 2005 Alyce Lomax	CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny.
The Motley Fool May 5, 2004 Mike Cianciolo	CVS Prescribes Growth The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins, and CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways.
The Motley Fool July 6, 2004 Steven Mallas	Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%.
The Motley Fool September 22, 2006 Ryan Fuhrmann	More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.
The Motley Fool May 18, 2004 Seth Jayson	Perky Days for J.C. Penney This cornerstone of the American mall is outrunning its rivals.
The Motley Fool March 5, 2004 Dave Marino-Nachison	Longs Coming Up Short Investors who bid on a Longs buyout haven't been rewarded in recent months.
The Motley Fool February 12, 2004 Dave Marino-Nachison	CVS Bags Big 2003 A strong year for the drugstore giant has spilled into January.
The Motley Fool May 9, 2005 Timothy M. Otte	Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note.
BusinessWeek January 12, 2004	Wayne Harris By now, Eckerd Corp. should have been nearly done with a three-year turnaround. After making early progress, Harris today finds himself back at square one.
The Motley Fool June 25, 2004 Steven Mallas	Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio?
The Motley Fool July 8, 2004 Alyce Lomax	J.C. Penney Rules June J.C. Penney succeeds in a month when many lower-priced retailers did not.
The Motley Fool September 14, 2006 Ryan Fuhrmann	Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.
The Motley Fool August 16, 2006 Ryan Fuhrmann	J.C. Penney Making Cents Is this 100-year-old retailer once again worth picking up? Investors, take note.
The Motley Fool February 25, 2005 Rich Duprey	Penney Beats by a Nickel Retailer J.C. Penney reports rising profits as it begins the last year of a five-year turnaround plan.
The Motley Fool January 5, 2004 Jeff Hwang	Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.
The Motley Fool May 16, 2006 Ryan Fuhrmann	What's in Store for J.C. Penney? Can Penney's recent profits translate into future dollars? Things have improved, but not enough for wise investors to pass up a chance to invest in faster-growing competitors with better business models.
The Motley Fool June 11, 2007 Mike Cianciolo	Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.
The Motley Fool November 10, 2004 Dave Marino-Nachison	Investors Adjusting to Larger CVS The drugstore company's chains have done nothing but rise since the Eckerd buy. Investors have pulled the company's shares steadily upward since the merger closed.
The Motley Fool June 21, 2004 Seth Jayson	Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore.
The Motley Fool July 7, 2004 Steven Mallas	CVS's Bright Picture Send CVS your digital photos over the Net, pick them up the next day. While competitors are sure to follow suit, this still shows how intellegent and creative this drugstore blue chip can be.
The Motley Fool April 8, 2004 Seth Jayson	Rite Aid Wrings Out Profits Net store closings and comps increases bring black ink to the pharmacy's bottom line.
The Motley Fool July 5, 2005 Alyce Lomax	Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.
The Motley Fool April 12, 2007 Ryan Fuhrmann	Rite Aid Ekes Out a Gain: Fool by Numbers The drugstore retailer released fourth-quarter and year-end 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool March 9, 2004 Alyce Lomax	February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers.
The Motley Fool September 24, 2004 Seth Jayson	Kick This Drug Habit Rite Aid offers slow sales and minuscule shareholder rewards.
The Motley Fool September 27, 2007 Ryan Fuhrmann	Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired.
The Motley Fool September 7, 2004 Seth Jayson	Rejecting Rite Aid Shares of the drugstore chain droped 13%, and may prove to be a bargain if this is indeed a temporary slowdown and management can deliver more robust growth.
The Motley Fool August 16, 2005 Rich Duprey	Penney Grows in Value Share repurchases fuel gains in J.C. Penney's latest respectable quarter.
The Motley Fool April 9, 2007 Mike Cianciolo	CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.
The Motley Fool February 3, 2006 Nathan Parmelee	CVS Looks Healthy The drugstore chain handles acquisitions without faltering -- this stock may be worth considering.
The Motley Fool January 8, 2007 Matthew Crews	CVS' Tightrope Walk The drugstore chain's aggressive growth strategy continues to pay off -- for now. Investors, take note.
CFO December 1, 2004 Tim Reason	A Penney Saved J. C. Penney has revamped its stores and store brands to bring customers, including younger ones, back after years of company decline. But while a deft turnaround buys time, what's in store long-term for the venerable retailer?
BusinessWeek September 19, 2005 Gene G. Marcial	CVS' Ever-Expanding Aisles According to analysts, the aging population and improving pipeline of new drugs will help the retail pharmacy achieve its goal of 15% overall long-term earnings growth. Investors, take note.
The Motley Fool March 28, 2005 Alyce Lomax	A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen?
The Motley Fool June 25, 2007 Ryan Fuhrmann	Foolish Forecast: Rite Aid Aims for Healthy Growth The drugstore operator is set to report its first-quarter earnings. Investors, here is what you can expect to see.
The Motley Fool April 13, 2007 Ryan Fuhrmann	Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial.
The Motley Fool September 27, 2004 Phil Wohl	Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27.
The Motley Fool September 26, 2006 Ryan Fuhrmann	Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?
The Motley Fool December 11, 2006 Matthew Crews	Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note.